Company Overview and News

14
John And Jane's July Dividend Increases And Income Tracker - Taxable Account

2018-08-13 seekingalpha
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM

0
Buckeye Partners: Strong Momentum For This 13% Yielding MLP

2018-08-13 seekingalpha
Our review of Buckeye Partners' earnings report. Management hired an external consultant to review its strategic options.
BPL

40
Stay Away From Coal Stocks - Cramer's Lightning Round (8/9/18)

2018-08-10 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, August 9.
DUKH DUK TRXC ISRG GDOT BPL AEP ABBV ED AAXN ABBV

4
Cramer Remix: Trade sanctions are hurting hedge funds the most

2018-08-09 cnbc
It may sound odd, but the group hurt the most by the U.S.-China trade war is the hedge funds, CNBC's Jim Cramer said on Thursday.
CYBR MGA WWE MG BPL

8
Cramer's lightning round: Coal's in a renaissance, but don't buy

2018-08-09 cnbc
Arch Coal, Inc.: "Coal is enjoying a bit of a renaissance, I have to admit. I am not a fan of the coal stocks, but these guys have fixed their balance sheet. I just don't want to overstate because even utilities in this country aren't that interested in it, so I say don't buy."
ACIIQ DUKH VC ACI AEP DUK ISRG ARCH AAXN BPL

2
Plains All American (PAA) Q2 Earnings Beat, Revenues Miss

2018-08-08 zacks
Plains All American Pipeline, L.P. (PAA - Free Report) reported second-quarter 2018 adjusted earnings of 38 cents per unit, beating the Zacks Consensus Estimate of 23 cents by 65.2%. Reported earnings surged 81% from 21 cents in the year-ago quarter. In the quarter under review, the partnership reported GAAP earnings of 7 cents compared with 21 cents in the year ago quarter. Total Revenues In the second quarter, the partnership reported total revenues of $8,080 million, which missed the Zacks Consensus Estimate of $8,182 million by 12.
OAS EPD PAA MMP BPL

1
BPL: Strongest Buy In MLP Universe

2018-08-07 seekingalpha
We show how we are playing the stock and why it makes sense in spite of fears.
ENB ETP WPZ DCF ENB BPL

13
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

2018-08-06 zacks
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported second-quarter 2018 earnings of 24 cents per share, surpassing the Zacks Consensus Estimate of 9 cents and the loss of 11 cents incurred a year ago.
EGRX JNJ PCRX VNDA HZNP BPL

5
Factors Setting the Tone for Shutterfly's (SFLY) Q2 Earnings

2018-08-06 zacks
Shutterfly, Inc. (SFLY - Free Report) is scheduled to report second-quarter 2018 numbers on Aug 7, after market close.
SINA A HZNP SFLY BPL ACXM

0
Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?

2018-08-06 zacks
Horizon Pharma plc (HZNP - Free Report) is scheduled to report second-quarter 2018 results on Aug 8, before the opening bell.
MDGL ENL HZNP BGSF BPL ENDP

1
Buckeye Partners (BPL) Q2 Earnings Lag, Sales Beat Estimates

2018-08-06 zacks
Buckeye Partners, L.P. (BPL - Free Report) reported second-quarter 2018 earnings of 59 cents per unit, lagging the Zacks Consensus Estimate of 69 cents by 14.5%. The bottom line was also lower than the year-ago figure of 80 cents by nearly 26.3%. Total Revenues In the quarter under review, Buckeye Partners’ total revenues came in at $940.8 million, beating the Zacks Consensus Estimate of $802 million by 17.
DKL NS HZNP BPL

6
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

2018-08-06 zacks
Emergent Biosolutions, Inc. (EBS - Free Report) delivered second-quarter 2018 earnings of $1.07 per share, surpassing the Zacks Consensus Estimate of 96 cents and the year-ago bottom-line figure of 13 cents.
EGRX EBS GSK HZNP GSK BGSF SNY BPL

4
Buckeye's (BPL) CEO Clark Smith on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Buckeye Partners, L.P. (NYSE:BPL) Q2 2018 Results Earnings Conference Call August 3, 2018 11:00 AM ET
WFC WFCNP BPL MS

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 118230101